Every 8-K that Crescent Biopharma, Inc. (CBIO) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow CBIO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CBIO filings page.
Crescent Biopharma reported Q2 2026 results with R&D expenses of $19.4 million and G&A expenses of $8.7 million, leading to a net loss of $24.8 million, or $0.74 per share, compared with a $21.8 million loss a year earlier. The company is advancing its oncology pipeline, including the ASCEND Phase 1/2 trial of CR-001, a PD-1 x VEGF bispecific antibody, and ADC programs CR-002 and CR-003, with multiple proof-of-concept and combination data readouts expected beginning in 2027.
Cash and cash equivalents were $171.6 million as of June 30, 2026, with pro forma cash of $305.1 million after a July 2026 public offering that generated $143.7 million in gross proceeds. Crescent expects this capital to fund operations into the second half of 2028, with approximately 33.5 million ordinary shares outstanding, or 43.5 million pro forma.
Crescent Biopharma, Inc. entered into an underwriting agreement for an underwritten public offering of ordinary shares and pre-funded warrants. The company is issuing 8,094,793 ordinary shares at $14.50 per share and, for certain investors, pre-funded warrants to purchase an aggregate of 525,897 ordinary shares at $14.499 per warrant.
The underwriters have a 30-day option to buy up to 1,293,103 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds are expected to be approximately $125.0 million, with estimated net proceeds of about $115.9 million, or $133.5 million if the option is fully exercised. The offering is expected to close on July 16, 2026, subject to customary conditions.
Each pre-funded warrant has a $0.001 exercise price, is immediately exercisable, does not expire, and includes beneficial ownership limitations of 4.99%, 9.99% or 19.99%. Crescent expects the net proceeds, together with existing cash, to fund operating, working capital and capital expenditure needs into the second half of 2028.
Crescent Biopharma, Inc. provides a preliminary estimate that cash and cash equivalents were approximately $171.6 million as of June 30, 2026. The figure is unaudited, based on management estimates for the quarter, and may change after completion of financial closing procedures.
The company states that its independent auditor, PricewaterhouseCoopers LLP, has not audited, reviewed, examined, compiled or applied procedures to this data. The information is treated as filed under Section 18 of the Exchange Act and incorporated by reference into certain securities law filings, and is accompanied by forward-looking statement cautions.
Crescent Biopharma, Inc. reported the results of its annual general meeting of shareholders held on June 2, 2026. Shareholders elected Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE as Class II directors to serve until the 2029 annual general meeting.
Investors also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved on a non-binding basis the compensation of named executive officers. Shareholders recommended holding future advisory votes on executive pay every year, and the Board agreed to follow an annual frequency.
Crescent Biopharma reported first quarter 2026 results alongside a detailed oncology pipeline update. The company is running its global Phase 1/2 ASCEND trial of CR-001, a PD-1 x VEGF bispecific antibody, across multiple solid tumors and preparing ADC combination trials beginning in the second half of 2026.
CR-002, a PD-L1–targeted ADC, is planned to enter the clinic in the second half of 2026, while CR-003, an ITGB6-targeted ADC, is already in a Phase 1/2 study in China. Multiple proof-of-concept data readouts are anticipated starting in early 2027.
Financially, Crescent ended March 31, 2026 with cash and cash equivalents of $189.2 million, which management expects will fund operations into 2028. Q1 2026 revenue was $1.0 million, research and development expense was $17.9 million, general and administrative expense was $7.9 million, and net loss was $23.3 million, or $0.70 per basic and diluted share.
Crescent Biopharma reported its fourth quarter and full year 2025 results, highlighting rapid pipeline expansion and heavy investment in oncology programs. The company generated $10.8 million in 2025 license revenue, all from a $20.0 million upfront payment under its CR-001 collaboration with Kelun-Biotech.
Research and development spending rose sharply to $138.1 million for 2025, driven by development of CR-001 and CR-002 and an $80.0 million upfront payment to Kelun-Biotech for CR-003. General and administrative expenses were $25.4 million, reflecting growth in headcount and public-company costs.
Crescent reported a full-year net loss of $153.9 million, or $12.81 per ordinary share. Cash and cash equivalents reached $213.2 million at December 31, 2025, supported by a $185 million private placement, which the company expects will fund operations into 2028. Around 33.3 million ordinary shares and equivalents were outstanding at year-end.
Operationally, Crescent advanced its immuno-oncology platform. The FDA cleared the IND for CR-001, and the first patient has been dosed in the global Phase 1/2 ASCEND trial in advanced solid tumors. The company expects proof-of-concept data from ASCEND in early 2027 and plans multiple additional Phase 1/2 trials for its ADC programs CR-002 and CR-003, including combination studies with CR-001.
Crescent Biopharma (CBIO) furnished an 8-K announcing its financial results for the quarter ended September 30, 2025. The results are provided in a press release attached as Exhibit 99.1.
The Company states this information is being furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference except as specifically set forth. The report is signed by CEO Joshua Brumm.